Jeong Gwang Hun, Lee Keum Hwa, Lee I Re, Oh Ji Hyun, Kim Dong Wook, Shin Jae Won, Kronbichler Andreas, Eisenhut Michael, van der Vliet Hans J, Abdel-Rahman Omar, Stubbs Brendon, Solmi Marco, Veronese Nicola, Dragioti Elena, Koyanagi Ai, Radua Joaquim, Shin Jae Il
College of Medicine, Gyeongsang National University, Jinju 52727, Korea.
Department of Pediatrics, Yonsei University College of Medicine, Yonsei-ro 50, Seodaemun-gu, C.P.O., Box 8044, Seoul 03722, Korea.
J Clin Med. 2019 Jan 26;8(2):143. doi: 10.3390/jcm8020143.
Capillary leak syndrome (CLS) is a rare disease with profound vascular leakage, which can be associated with a high mortality. There have been several reports on CLS as an adverse effect of anti-cancer agents and therapy, but the incidence of CLS according to the kinds of anti-cancer drugs has not been systemically evaluated. Thus, the aim of our study was to comprehensively meta-analyze the incidence of CLS by different types of cancer treatment or after bone marrow transplantation (BMT). We searched the literatures (inception to July 2018) and among 4612 articles, 62 clinical trials (studies) were eligible. We extracted the number of patients with CLS, total cancer patients, name of therapeutic agent and dose, and type of cancer. We performed a meta-analysis to estimate the summary effects with 95% confidence interval and between-study heterogeneity. The reported incidence of CLS was categorized by causative drugs and BMT. The largest number of studies reported on CLS incidence during interleukin-2 (IL-2) treatment ( = 18), which yielded a pooled incidence of 34.7% by overall estimation and 43.9% by meta-analysis. The second largest number of studies reported on anti-cluster of differentiation (anti-CD) agents ( = 13) (incidence of 33.9% by overall estimation and 35.6% by meta-analysis) or undergoing BMT ( = 7 (21.1% by overall estimation and 21.7% by meta-analysis). Also, anti-cancer agents, including IL-2 + imatinib mesylate (three studies) and anti-CD22 monoclinal antibodies (mAb) (four studies), showed a dose-dependent increase in the incidence of CLS. Our study is the first to provide an informative overview on the incidence rate of reported CLS patients as an adverse event of anti-cancer treatment. This meta-analysis can lead to a better understanding of CLS and assist physicians in identifying the presence of CLS early in the disease course to improve the outcome and optimize management.
毛细血管渗漏综合征(CLS)是一种罕见疾病,伴有严重的血管渗漏,病死率可能很高。已有多篇关于CLS作为抗癌药物和治疗的不良反应的报道,但尚未对不同种类抗癌药物导致CLS的发生率进行系统评估。因此,我们研究的目的是对不同类型癌症治疗或骨髓移植(BMT)后CLS的发生率进行全面的荟萃分析。我们检索了相关文献(从起始到2018年7月),在4612篇文章中,有62项临床试验(研究)符合条件。我们提取了CLS患者数量、癌症患者总数、治疗药物名称及剂量以及癌症类型。我们进行了荟萃分析以估计汇总效应及95%置信区间和研究间异质性。报告的CLS发生率按致病药物和BMT进行分类。关于CLS发生率的研究中,报道数量最多的是白细胞介素-2(IL-2)治疗期间(n = 18),总体估计汇总发生率为34.7%,荟萃分析为43.9%。报道数量第二多的是抗分化簇(抗-CD)药物(n = 13)(总体估计发生率为33.9%,荟萃分析为35.6%)或接受BMT(n = 7)(总体估计发生率为21.1%,荟萃分析为21.7%)。此外,包括IL-2 + 甲磺酸伊马替尼(三项研究)和抗CD22单克隆抗体(mAb)(四项研究)在内的抗癌药物,显示CLS发生率呈剂量依赖性增加。我们的研究首次提供了关于作为抗癌治疗不良事件的CLS报告患者发生率的信息性概述。这项荟萃分析有助于更好地了解CLS,并协助医生在疾病过程早期识别CLS的存在,以改善预后并优化管理。